• 1
    Rauch F, Glorieux FH 2004 Osteogenesis Imperfecta. Lancet 363: 6137761385.
  • 2
    Gatti D, Colapietro F, Fracassi E, Sartori E, Antoniazzi F, Braga V, Rossini M, Adami S 2003 The volumetric bone density and cortical thickness in adult patients with osteogenesis imperfecta. J Clin Densitom 6: 173177.
  • 3
    Adami S, Gatti D, Colapietro F, Fracassi E, Braga V, Rossini M, Tatò L 2003 Intravenous neridronate in adults with osteogenesis imperfecta. J Bone Miner Res 18: 126130.
  • 4
    Adami S, Gatti D, Antoniazzi F, Colapietro F, Fracassi E, Braga V, Rossini M, Tatò L 2005 Intravenous neridronate in children with osteogenesis imperfecta: A randomized control study. J Bone Miner Res 20: 758763.
  • 5
    Delmas PD, Zhengqing LI, Cooper C 2004 Relationship between changes in bone mineral density and fracture risk reduction with antiresorptive drugs: Some issues with meta-analyses. J Bone Miner Res 19: 330337.
  • 6
    Gatti D, Rossini M, Zamberlan N, Braga V, Fracassi E, Adami S 1996 Effects of aging on trabecular and compact bone components of proximal and ultradistal radius. Osteoporos Int 6: 355360.
  • 7
    Jiang Y, Zhao JJ, Mitlak BH, Wang O, Genant HK, Eriksen EF 2003 Recombinant human parathyroid hormone (1–34) (teriparatide) improves both cortical and cancellous bone structure. J Bone Miner Res 18: 19321941.
  • 8
    Adami S, Kanis JA 1995 Perspectives: Assessment of involutional bone loss: Methodological and conceptual problems. J Bone Miner Res 10: 511517.